Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893337 | PMC |
| http://dx.doi.org/10.1016/j.lanepe.2025.101244 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Opportunities for European medical societies within the European Global Health strategy.
Lancet Reg Health Eur
March 2025
Onco-Hematology Laboratory, Université Paris Cité, Assistance Publique - Hôpitaux de Paris, France.
Sex hormones, the anticancer immune response, and therapeutic opportunities.
Cancer Cell
March 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IRCCS Humanitas Research Hospital, Rozzano, Italy; William Harvey Research Institute, Queen Mary University, London, UK.
Sex-based differences have been observed in the incidence and prognosis of various cancers, as well as in the response to immune check point inhibitors (ICIs). These disparities are partially attributed to sex-based differences in the molecular characteristics of the anticancer immune response, which are largely influenced by sex hormones. Here, we provide a comprehensive overview on how sex hormones affect innate and adaptive immunity and contribute to shaping the features of tumor immune microenvironment and response to anticancer immunotherapy.
View Article and Find Full Text PDFControl of HIV across the WHO European region: progress and remaining challenges.
Lancet Reg Health Eur
May 2025
Department of Internal Medicine I, Universitätsklinkum Bonn, Bonn, Germany.
Despite the ambitious global goal to control HIV transmissions by 2030, more than 30% of people with HIV from the WHO European Region show persistent transmissible levels of the virus. Successful introduction of oral pre-exposure prophylaxis (PrEP) has led to significant decreases in new HIV transmissions in some areas of Europe, particularly among men who have sex with men. However, the limited PrEP access or lack of state funding in many European countries underlines the need to increase efforts to make PrEP consistently and equitably available for all individuals in need.
View Article and Find Full Text PDFToward the use of nanopore RNA sequencing technologies in the clinic: challenges and opportunities.
Nucleic Acids Res
February 2025
Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain.
RNA molecules have garnered increased attention as potential clinical biomarkers in recent years. While short-read sequencing and quantitative polymerase chain reaction have been the primary methods for quantifying RNA abundance, they typically fail to capture critical post-transcriptional regulatory elements, such as RNA modifications, which are often dysregulated in disease contexts. A promising cutting-edge technique sequencing method that addresses this gap is direct RNA sequencing, offered by Oxford Nanopore Technologies, which can simultaneously capture both RNA abundance and modification information.
View Article and Find Full Text PDFBuilding and Developing a Tool (PANDEM-2 Dashboard) to Strengthen Pandemic Management: Participatory Design Study.
JMIR Public Health Surveill
March 2025
School of Health Sciences, University of Galway, Galway, Ireland.
Background: The COVID-19 pandemic exposed challenges in pandemic management, particularly in real-time data sharing and effective decision-making. Data protection concerns and the lack of data interoperability and standardization hindered the collection, analysis, and interpretation of critical information. Effective data visualization and customization are essential to facilitate decision-making.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!